Tequin Lawyers
When placed on the market by Bristol-Myers Squibb in 1999, Tequin® was promoted as a new and effective antibiotic for the treatment of lung, sinus and urinary tract infections as well as certain sexually transmitted diseases, including gonorrhea.Bristol-Myers Squibb claims the decision to stop making Tequin® was based on "marketing reasons," but the evidence suggests a broad range of health problems strongly linked to the drug. In addition to increased risk factors involving tendon ruptures, hypoglycemia, and hyperglycemia, Tequin® has been linked to serious adverse side effect risks, which include severe and sometimes fatal allergic reactions, dangerous diarrhea, cardiovascular complications, and central nervous system side effects such as seizures and psychosis.
Tequin Lawyers By State
Click here to view State Links
